

September 2, 2025

Company name: Alivexis, Inc.  
Representative: S. Roy Kimura, Ph.D., CEO

**Alivexis Announces Receipt of Intention to Exercise Option Right from Astellas Pharma Inc. for Collaboration on Novel Drug Target**

News – September 2, 2025 - Alivexis, Inc. (Headquartered in Minato-ku, Tokyo; CEO S. Roy Kimura) is pleased to announce they have received a notice from Astellas Pharma Inc. ("Astellas") to exercise the option right granted under a Research Collaboration Agreement, executed on June 17<sup>th</sup> 2024. This agreement focused on identifying small molecule compounds targeting a new drug target selected by Astellas, utilizing Alivexis' drug discovery platform ModBind™ and other advanced technologies.

The joint research collaboration aimed to accelerate the discovery of novel functional modulators for a previously uncharacterized drug target selected by Astellas. Leveraging our computational drug discovery platform, including ModBind™, the Alivexis team led the integrated drug discovery researching, including conducting *in silico* evaluations and developing experimental assays to evaluate compound efficacy. Under the terms of the collaboration agreement, Astellas was granted the option to acquire rights to the research deliverables.

**About ModBind™.**

Alivexis has established a computational drug discovery platform that greatly accelerates small molecule drug discovery, which includes physics-based molecular dynamics simulations using GPUs (Graphics Processing Units), large-scale virtual screening algorithms, and deep learning models. With the help of their computational drug discovery platform, Alivexis has already delivered several clinical candidate molecules for both in-house drug discovery projects and external collaborations. Among Alivexis' various computational drug discovery tools, the newly developed ModBind™ is a molecular simulations-based algorithm that can predict the efficacy of drug candidate compounds with high accuracy, yet performs hundreds to thousands of times faster than the other state-of-the-art technologies in the field. ModBind™ is based on a theoretical approach that is fundamentally different from industry standard simulations-based prediction technologies. One significant advantage of ModBind™ is that it is an absolute predictor of ligand efficacy and does not require known reference compounds, which are usually necessary for other methodologies. Therefore,



ModBind™ is useful in all stages of preclinical drug discovery – from screening large random chemical libraries for initial hit finding to delivering clinical candidates in the lead-optimization stage. This capability has already been proven by Alivexis' in-house research and external collaborations and is contributing to the progression of many drug discovery projects.

### **【CEO S. Roy Kimura's Comments】**

“We are extremely pleased that Astellas Pharma has elected to exercise its option to obtain the rights for the small molecule compounds that were discovered through our ModBind™ drug discovery collaboration. Despite being a difficult target with no previously reported lead compounds, our ModBind™ simulation technology has successfully identified compounds worth further study. This result further demonstrates the power of our ModBind™ platform to rapidly identify promising drug lead compounds. Beyond identifying new drug candidates for other promising disease targets, we are currently applying ModBind™ to develop a foundation AI model for drug discovery and generate very large synthetic datasets to train target-specific generative AI models. We believe that the combination of simulation and AI (ModBind™xAI) is the key to unlocking efficient drug discovery.”

### **About Alivexis, Inc.:**

Name: Alivexis, Inc.

Headquarter: Daiichi Hibiya Building 7F Shimbashi 1-18-21, Minato-ku, Tokyo 105-0004, Japan

Representative directors: S. Roy Kimura, Ph.D., CEO / Kazuki Ohno, Dr. Eng. COO

Established: August 8, 2016

URL: <https://alivexis.com>

Business Description: A network-based drug discovery company utilizing cutting-edge technologies.

<p>Contact Information</p> <p>Business Administration Division</p> <p><a href="mailto:info@alivexis.com">info@alivexis.com</a></p>
--